<DOC>
	<DOCNO>NCT02575560</DOCNO>
	<brief_summary>EGFR-TKI main first line therapy local advance metastatic non-small cell lung cancer EGFR gene mutation . The median progression free survival time around 11 month first generation EGFR-TKI . Patients acquire resistance first generation EGFR-TKI usually EGFR exon 20 mutation ( T790M ) . Change drug administration maybe prolong patient PFS evently prolong OS .</brief_summary>
	<brief_title>Weekly Use First-generation EGFR-TKI Treatment EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>1st generation EGFR-TKI reversible binding EGFR , also bind T790M high dose account 60 % patient acquire resistance drug . Resistance patient may benefit bolus drug use block T790M gene .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>NSCLC EGFR mutation progress first generation EGFRTKI , progress chemotherapy 1st generation EGFRTKI progress 1st generation EGFRTKI chemotherapy . Expected survival 3 month ECOG â‰¤3 . liver function ( ALT , AST ) renal function 2 time higher normal limit ; IPD ; uncontrolled diarrhea ; severe anemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Progression-Free Survival</keyword>
</DOC>